#China #Shanghai #financial results #WuXi AppTec #CRDMO

WuXi AppTec Financial Highlights for Q1-Q3 2025

WuXi AppTec has recently reported its financial results for the first three quarters of 2025, indicating substantial growth in both revenue and profit. The company, a prominent player in the pharmaceutical and life sciences sectors, achieved a total revenue of RMB 32.86 billion, reflecting an impressive 18.6% increase year over year. Revenue from continuing operations also rose sharply to RMB 32.45 billion, up by 22.5% compared to the same period last year.

The financial metrics also highlight a notable boost in net profit attributable to the company’s owners, which reached RMB 12.08 billion, marking an 84.8% increase year on year. This growth translated into a diluted earnings per share (EPS) of RMB 4.21, up by 87.9% from the previous year. These figures showcase the company's robust performance and strong operational efficiency, establishing WuXi AppTec as a leader in the Contract Research, Development, and Manufacturing Organization (CRDMO) space.

Revenue Growth Drivers

One of the key factors contributing to WuXi AppTec's impressive growth is the significant backlog for continuing operations, which reached RMB 59.88 billion as of September 30, 2025, reflecting a 41.2% increase year over year. This backlog indicates ongoing demand for its services and highlights the firm’s ability to meet customer needs effectively. Additionally, the company reported an operating cash flow of RMB 10.87 billion, a year-over-year increase of 35%, largely driven by enhanced operational efficiencies.

WuXi Chemistry, the company's CRDMO segment, showed particularly strong performance, with Q1-Q3 revenue reaching RMB 25.98 billion, representing a 29.3% increase year on year. This segment's growth reflects the strategic focus on late-stage clinical and commercial projects and increased capacity utilization. The adjusted non-IFRS gross profit margin for WuXi Chemistry improved to 51.3%, further underscoring its solid operational performance.

Commitment to Shareholder Returns

In addition to its strong financial results, WuXi AppTec has demonstrated a commitment to rewarding its shareholders. The company implemented a total of RMB 6.88 billion in cash dividends, share repurchases, and cancellations, equating to over 70% of its 2024 net profit. Of this amount, RMB 4.88 billion was distributed in cash dividends, evidencing the company's commitment to enhancing shareholder value.

Strategic Outlook for 2025

Looking ahead, WuXi AppTec is optimistic about its growth trajectory, raising its full-year guidance for 2025. The firm anticipates continued double-digit growth in its continuing operations, increasing its growth expectation to 17-18%, up from the previous 13-17% forecast. This revised outlook is bolstered by demand for its CRDMO business model and ongoing improvements in operational efficiencies. With strong market fundamentals and a robust pipeline, WuXi AppTec is well-positioned to meet its ambitious objectives.

Dr. Ge Li, the Chairman and CEO of WuXi AppTec, expressed confidence in the company's ongoing performance. He highlighted that sustained growth in revenue, profit, and operational cash flow attests to the enduring strength of WuXi’s unique business model, designed to cater effectively to evolving market demands. He reiterated the company's vision, stating, 'Every drug can be made and every disease can be treated.'

In conclusion, WuXi AppTec's impressive financial results for Q1-Q3 2025 illustrate its strong market position and capability to drive growth while enhancing shareholder value. With a solid business strategy and commitment to operational excellence, the company is poised for continued success in the pharmaceutical and life sciences industries.